Nothing Special   »   [go: up one dir, main page]

MX2017001674A - Inhibidores de myh7b y usos de los mismos. - Google Patents

Inhibidores de myh7b y usos de los mismos.

Info

Publication number
MX2017001674A
MX2017001674A MX2017001674A MX2017001674A MX2017001674A MX 2017001674 A MX2017001674 A MX 2017001674A MX 2017001674 A MX2017001674 A MX 2017001674A MX 2017001674 A MX2017001674 A MX 2017001674A MX 2017001674 A MX2017001674 A MX 2017001674A
Authority
MX
Mexico
Prior art keywords
myh7b
subject
present
administering
inhibitor
Prior art date
Application number
MX2017001674A
Other languages
English (en)
Inventor
Montgomery Rusty
Dalby Christina
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of MX2017001674A publication Critical patent/MX2017001674A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención actual proporciona inhibidores de ácido nucleico de MYH7B y composiciones de los mismos. La invención actual también proporciona métodos para tratar o prevenir un trastorno cardiaco tal como hipertrofia cardiaca, infarto al miocardio, o insuficiencia cardiaca en un sujeto al administrar al sujeto un inhibidor de MYH7B. La invención actual proporciona además métodos para modular la actividad o expresión de ß-MHC en células cardiacas de un sujeto al administrar al sujeto un inhibidor de MYH7B.
MX2017001674A 2014-08-04 2015-08-04 Inhibidores de myh7b y usos de los mismos. MX2017001674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033018P 2014-08-04 2014-08-04
PCT/US2015/043571 WO2016022536A2 (en) 2014-08-04 2015-08-04 Inhibitors of myh7b and uses thereof

Publications (1)

Publication Number Publication Date
MX2017001674A true MX2017001674A (es) 2017-08-10

Family

ID=55179393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001674A MX2017001674A (es) 2014-08-04 2015-08-04 Inhibidores de myh7b y usos de los mismos.

Country Status (11)

Country Link
US (2) US9752144B2 (es)
EP (1) EP3177327A4 (es)
JP (1) JP6637961B2 (es)
KR (1) KR20170042625A (es)
CN (1) CN108064175A (es)
AR (1) AR101449A1 (es)
AU (1) AU2015301221B2 (es)
CA (1) CA2957618A1 (es)
MX (1) MX2017001674A (es)
TW (1) TW201614069A (es)
WO (1) WO2016022536A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001674A (es) 2014-08-04 2017-08-10 Miragen Therapeutics Inc Inhibidores de myh7b y usos de los mismos.
CA2958524A1 (en) * 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
WO2019126315A1 (en) * 2017-12-19 2019-06-27 The Regents Of The University Of Michigan Cardiac microtissue and uses thereof
EP3813844A1 (en) * 2018-06-28 2021-05-05 United Kingdom Research and Innovation Treatment of cardiomyopathy through modulation of hypoxia-induced erna activity
EP3829594A4 (en) * 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6639062B2 (en) * 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
SK17432000A3 (sk) 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6716242B1 (en) 1999-10-13 2004-04-06 Peter A. Altman Pulmonary vein stent and method for use
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6589286B1 (en) 2001-09-12 2003-07-08 Jason Litner Eustachian tube stent
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
EP2298358A1 (en) 2002-05-06 2011-03-23 Alnylam Pharmaceuticals Inc. Methods for delivery of nucleic acids
US20040133270A1 (en) 2002-07-08 2004-07-08 Axel Grandt Drug eluting stent and methods of manufacture
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7144422B1 (en) 2002-11-13 2006-12-05 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7105018B1 (en) 2002-12-30 2006-09-12 Advanced Cardiovascular Systems, Inc. Drug-eluting stent cover and method of use
US7156869B1 (en) 2003-01-27 2007-01-02 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and delivery system with tapered stent in shoulder region
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
US7055237B2 (en) 2003-09-29 2006-06-06 Medtronic Vascular, Inc. Method of forming a drug eluting stent
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
CA2557480A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US7842800B2 (en) * 2004-04-02 2010-11-30 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
AU2006292524A1 (en) 2005-09-15 2007-03-29 Duke University Focused libraries, functional profiling, laser selex and deselex
CA2889540A1 (en) 2005-09-15 2007-03-22 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
BRPI0719995A2 (pt) * 2006-12-14 2014-03-18 Novartis Ag Composições e métodos para tratar distúrbios musculares & cardiovasculares
NZ583025A (en) * 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity
NZ583677A (en) * 2007-10-04 2012-06-29 Santaris Pharma As MicroRNAs comprising Locked Nucleic Acid (LNA) units
MX2011008190A (es) * 2009-02-04 2011-10-06 Univ Texas Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
EP3165606A1 (en) * 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
EP2611918A1 (en) * 2010-05-28 2013-07-10 Vereniging Voor Christelijk Hoger Onderwijs, Weten Mirnas involved in the blood brain barrier function
AU2011343720A1 (en) * 2010-12-15 2013-04-11 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
WO2012140234A1 (en) 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
MX353322B (es) * 2011-09-20 2018-01-05 Ionis Pharmaceuticals Inc Modulacion antisentido de la expresion de gcgr.
JP6177243B2 (ja) * 2011-10-06 2017-08-09 ミラゲン セラピューティクス, インコーポレイテッド マイクロrnaの調節による全身エネルギーホメオスタシスの制御
CA2871073A1 (en) * 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Mirna modulators of thermogenesis
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
EA201492117A1 (ru) * 2012-05-16 2015-04-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии bdnf
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
KR101928418B1 (ko) * 2012-06-21 2018-12-12 미라젠 세러퓨틱스 인코포레이티드 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제
MX2017001674A (es) 2014-08-04 2017-08-10 Miragen Therapeutics Inc Inhibidores de myh7b y usos de los mismos.

Also Published As

Publication number Publication date
US20180094262A1 (en) 2018-04-05
EP3177327A2 (en) 2017-06-14
AU2015301221A1 (en) 2017-03-02
US10144930B2 (en) 2018-12-04
KR20170042625A (ko) 2017-04-19
JP6637961B2 (ja) 2020-01-29
WO2016022536A2 (en) 2016-02-11
CA2957618A1 (en) 2016-02-11
JP2017528441A (ja) 2017-09-28
AU2015301221B2 (en) 2020-07-02
CN108064175A (zh) 2018-05-22
US9752144B2 (en) 2017-09-05
US20160032286A1 (en) 2016-02-04
AR101449A1 (es) 2016-12-21
WO2016022536A3 (en) 2016-03-31
TW201614069A (en) 2016-04-16
EP3177327A4 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
MX2017001674A (es) Inhibidores de myh7b y usos de los mismos.
MX2018005829A (es) Composiciones para tratar el cabello.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX2018013983A (es) Inhibidores g12c de kras.
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
MX2017016819A (es) Composiciones antimicrobianas y sus usos.
AU2015374459A8 (en) Picolinamide compounds with fungicidal activity
NZ732799A (en) Picolinamides with fungicidal activity
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX2015003874A (es) Modulacion de ire1.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
PH12014502513A1 (en) Nampt inhibitors
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MA39824A (fr) Composés azole amido-substitués
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2015168617A3 (en) Compositions and methods for modulating mtorc1
MY177290A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EA201790969A1 (ru) Способы и композиции для безопасного и эффективного тромболизиса